Abstract
Nasopharyngeal carcinoma (NPC) is one of the most prevailing cancers in southern China and southern Asia. Because of the nonspecific symptoms and lack of effective biomarker, most patients are diagnosed at advanced stages, resulting in poor 5-year survival rate. To identify a novel NPC biomarker facilitating early detection and effective therapy of NPC, a two-step strategy consisting of cancer cell-Systematic Evolution of Ligands by EXponential enrichment (cell-SELEX) procedure and aptamer-based purification approach was developed. Using cell-SELEX procedure, four aptamers (S3, S5, S12 and S27) differentiating the molecular differences between NPC cells and NP cells were successfully screened. Then, using aptamer-based protein purification, membrane protein CD109 was identified as the target of aptamer S3. CD109 protein was further identified to be over-expressed in NPC cell lines and clinic tissues, but not or low in NP cell line and clinic NP tissues, detected by western blot and immunohistochemistry experiments. Our study demonstrated that CD109 identified by cell-SELEX and aptamer-based purification strategy might be used as a potential NPC biomarker for early diagnosis and targeted therapy.
Highlights
Nasopharyngeal carcinoma (NPC) is a squamouscell carcinoma that occurs in the epithelia lining of nasopharynx [1]
Our study demonstrated that CD109 identified by cell-Systematic Evolution of Ligands by EXponential enrichment (SELEX) and aptamer-based purification strategy might be used as a potential NPC biomarker for early diagnosis and targeted therapy
To generate NPC cells-recognizing aptamers, a cellSELEX process was directed against NPC 5-8F cell line, with nonmalignant NP69 cell line as negative control
Summary
Nasopharyngeal carcinoma (NPC) is a squamouscell carcinoma that occurs in the epithelia lining of nasopharynx [1]. The prognosis for patients with NPC depends on the stage of the disease at diagnosis [4]. Due to minimal or non-specific local symptoms and the relative inaccessibility of the nasopharynx for routine examination, most NPC patients are diagnosed at advanced stage, resulting in poor prognosis and low survival rate [5]. Based on the close relation between NPC and Epstein-Barr Virus (EBV), EBV DNA in plasma or serum has been suggesting as a marker for diagnosis of primary NPC, monitoring of disease relapse and screening of the high-risk population over the past 14 www.impactjournals.com/oncotarget years [6]. Low reproducibility of quantitative plasma EBV DNA results among different laboratories has limited its clinical applications [5]. Discovering biomarkers for early diagnosis of NPC becomes critical to improve the overall survival of NPC patients
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
